Compassionate use access for odronextamab
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This program provides access to an experimental drug (odronextamab) for people who have run out of approved options. It may help if your doctor thinks the potential benefit is worth trying.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious or life-threatening condition for which no approved treatment is available.
- You have tried all standard treatment options without success or you cannot tolerate them.
- Your doctor believes the potential benefit of the drug outweighs the risks for you.
- You are able to participate in a program that monitors your health closely.
- You are not eligible for an existing clinical trial of this same drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
This program provides access to an experimental drug called selinexor for patients who have tried other treatments and have no other options. The goal is to give patients a chance to try this medication while it is still being studied.
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
This trial tests a drug called odronextamab for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. It aims to see if the drug can help before and after a type of immunotherapy called CAR T-cell therapy.
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
This trial tests a drug called odronextamab for people with large B-cell lymphoma whose cancer did not respond to or came back after initial treatment. The goal is to see if odronextamab can help shrink the tumor before getting CAR-T cell therapy.
Hear when a new Relapsed or Refractory (R/R) Follicular Lymphoma (FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.